PT1157023E - Epotilonas modificadas em c-21 - Google Patents

Epotilonas modificadas em c-21

Info

Publication number: PT1157023E
Authority: PT; Portugal
Prior art keywords: epotilones; modified; modified epotilones
Prior art date: 1999-02-22

Application number

PT00910219T

Other languages

English (en)

Inventor

Thomas Leibold

Gerhard Hoefle

Nicole Glase

Gregory Vite

Soong-Hoon Kim

Original Assignee

Bristol Myers Squibb Co

Biotechnolog Forschung Mbh Gbf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-22

Filing date

2000-02-17

Publication date

2004-03-31

1999-02-22 Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de

1999-07-01 Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de

2000-02-17 Application filed by Bristol Myers Squibb Co, Biotechnolog Forschung Mbh Gbf filed Critical Bristol Myers Squibb Co

2004-03-31 Publication of PT1157023E publication Critical patent/PT1157023E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

PT00910219T 1999-02-22 2000-02-17 Epotilonas modificadas em c-21 PT1157023E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE1999107588 DE19907588A1 (de)	1999-02-22	1999-02-22	C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de)	1999-07-01	1999-07-01	C-21 Modifizierte Epothilone

Publications (1)

Publication Number	Publication Date
PT1157023E true PT1157023E (pt)	2004-03-31

Family

ID=26051995

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00910219T PT1157023E (pt)	1999-02-22	2000-02-17	Epotilonas modificadas em c-21

Country Status (37)

Country	Link
US (1)	US6262094B1 (pt)
EP (1)	EP1157023B1 (pt)
JP (1)	JP4598957B2 (pt)
KR (1)	KR100685336B1 (pt)
CN (1)	CN1205208C (pt)
AR (1)	AR028815A1 (pt)
AT (1)	ATE254615T1 (pt)
AU (1)	AU771089B2 (pt)
BG (1)	BG64987B1 (pt)
BR (1)	BR0008379A (pt)
CA (1)	CA2360452C (pt)
CO (1)	CO5140093A1 (pt)
CZ (1)	CZ301498B6 (pt)
DE (1)	DE60006649T2 (pt)
DK (1)	DK1157023T3 (pt)
EE (1)	EE04852B1 (pt)
ES (1)	ES2209831T3 (pt)
GE (1)	GEP20033067B (pt)
HK (1)	HK1038923B (pt)
HU (1)	HUP0200076A3 (pt)
ID (1)	ID29829A (pt)
IL (1)	IL144501A0 (pt)
LT (1)	LT4944B (pt)
LV (1)	LV12755B (pt)
MX (1)	MXPA01008374A (pt)
MY (1)	MY120601A (pt)
NO (1)	NO320806B1 (pt)
NZ (1)	NZ513629A (pt)
PE (1)	PE20001546A1 (pt)
PL (1)	PL212545B1 (pt)
PT (1)	PT1157023E (pt)
RU (1)	RU2253652C2 (pt)
SK (1)	SK287200B6 (pt)
TR (1)	TR200102401T2 (pt)
TW (1)	TWI270546B (pt)
UY (1)	UY26024A1 (pt)
WO (1)	WO2000050423A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1196698C (zh) *	1996-11-18	2005-04-13	生物技术研究有限公司(Gbf)	Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en)	1996-12-03	2001-06-05	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) *	1998-05-18	1998-07-15	Ciba Geigy Ag	Organic compounds
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) *	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
BR0114065A (pt)	2000-09-22	2003-07-22	Biotechnolog Forschung Gmbh	Triazolo-epotilonas
IL155306A0 (en) *	2000-10-13	2003-11-23	Univ Mississippi	Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
CZ20032022A3 (cs)	2001-01-25	2004-04-14	Bristol-Myers Squibb Company	Parenterální prostředek obsahující epothilonová analoga
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
IL157128A0 (en) *	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
PL363362A1 (en)	2001-02-20	2004-11-15	Bristol-Myers Squibb Company	Treatment of refractory tumors using epothilone derivatives
CN1496256A (zh) *	2001-03-14	2004-05-12	��˹�ж�-��˹˹��˾	用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合
JP2005513167A (ja) *	2002-01-14	2005-05-12	ノバルティスアクチエンゲゼルシャフト	エポシロン誘導体と代謝拮抗剤からなる組合せ
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) *	2002-03-01	2005-05-31	University Of Notre Dame	Derivatives of epothilone B and D and synthesis thereof
SI1485090T1 (sl) *	2002-03-08	2008-06-30	Novartis Ag	Kombinacija vključujoča derivat epotilona in imidazotetrazinon
PL371098A1 (en) *	2002-03-08	2005-06-13	Novartis Ag	Combinations comprising epothilone derivatives and alkylating agents
WO2003078411A1 (en)	2002-03-12	2003-09-25	Bristol-Myers Squibb Company	C3-cyano epothilone derivatives
WO2003077903A1 (en) *	2002-03-12	2003-09-25	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
DE60328772D1 (de) *	2002-05-01	2009-09-24	Novartis Ag	Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) *	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CN102532120A (zh)	2002-08-23	2012-07-04	索隆-基特林癌症研究协会	埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
KR20050053681A (ko)	2002-09-23	2005-06-08	브리스톨-마이어스 스큅 컴퍼니	에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
JP2006504745A (ja) *	2002-10-09	2006-02-09	コーザンバイオサイエンシスインコーポレイテッド	エポｄ及び５−ｆｕ／ゲムシタビン
EP1594854B1 (en)	2003-02-06	2010-09-01	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en)	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) *	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en)	2004-03-16	2004-04-21	Novartis Ag	Organic compounds
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) *	2004-05-18	2009-01-01	Franchini Miriam K	Nanoparticle dispersion containing lactam compound
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20060134214A1 (en) *	2004-11-18	2006-06-22	Ismat Ullah	Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
PE20061058A1 (es) *	2004-11-18	2006-10-13	Bristol Myers Squibb Co	Composicion farmaceutica que comprende ixabepilona y proceso de preparacion
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
US8003801B2 (en) *	2005-11-22	2011-08-23	The Scripps Research Institute	Chemical synthesis of a highly potent epothilone
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
NZ572836A (en)	2006-05-16	2011-12-22	Pharmascience Inc	Iap bir domain binding compounds
US20100099090A1 (en) *	2007-03-05	2010-04-22	Bristol-Mayers Squibb Company	Biomarkers and methods for determining sensitivity to ctla-4 antagonists
US8143415B2 (en) *	2007-05-25	2012-03-27	Bristol-Myers Squibb Company	Processes for making epothilone compounds and analogs
WO2009089260A2 (en)	2008-01-08	2009-07-16	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CN104116736A (zh) *	2008-04-24	2014-10-29	百时美施贵宝公司	埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
MX2010012579A (es) *	2008-05-29	2010-12-20	Squibb Bristol Myers Co	Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora.
US8119129B2 (en) *	2008-08-01	2012-02-21	Bristol-Myers Squibb Company	Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
SI2769737T1 (sl)	2009-07-20	2017-06-30	Bristol-Myers Squibb Company	Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
EP2496567B1 (en)	2009-11-05	2017-07-12	Rhizen Pharmaceuticals S.A.	Novel benzopyran kinase modulators
AU2011214057B2 (en)	2010-02-12	2016-11-17	Pharmascience Inc.	IAP BIR domain binding compounds
EP2571878B1 (en)	2010-05-17	2018-10-17	Incozen Therapeutics Pvt. Ltd.	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
US20130064831A1 (en)	2010-05-17	2013-03-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
CA2927832C (en)	2010-05-18	2021-03-23	Cerulean Pharma Inc.	Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
LT2705029T (lt)	2011-05-04	2019-02-11	Rhizen Pharmaceuticals S.A.	Naujieji junginiai, kaip baltymų kinazės moduliatoriai
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
CN107082779A (zh)	2012-03-30	2017-08-22	理森制药股份公司	作为c‑met 蛋白激酶调节剂的新化合物
US9725477B2 (en)	2012-11-17	2017-08-08	Beijing Fswelcome Technology Development Co., Ltd	Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en)	2013-03-15	2015-10-01	Memorial Sloan-Kettering Cancer Center	HSP90-targeted cardiac imaging and therapy
EP3066127A1 (en)	2013-11-06	2016-09-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
CA2969665A1 (en)	2014-12-04	2016-06-09	Bristol-Myers Squibb Company	Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
US10925867B2 (en)	2015-06-29	2021-02-23	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer
CN105153177B (zh) *	2015-09-28	2017-08-08	湖南大学	呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en)	2016-05-11	2017-11-16	Movassaghi Mohammad	Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE75883C (de)			W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen	Ofen zur Erzeugung von Cyanammonium
DE301115C (pt)
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
US6288237B1 (en)	1995-11-17	2001-09-11	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epothilons C and D, preparation and compositions
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
WO1998008849A1 (de)	1996-08-30	1998-03-05	Novartis Aktiengesellschaft	Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
CN1196698C (zh) *	1996-11-18	2005-04-13	生物技术研究有限公司(Gbf)	Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en)	1996-12-03	2001-06-05	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
DE19707303B4 (de)	1997-02-11	2006-05-11	Mitteldeutsches Bitumenwerk Gmbh	Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
CA2281105A1 (en)	1997-02-25	1998-09-03	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epothilones with a modified side chain
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
DE59805900D1 (de)	1997-04-18	2002-11-14	Studiengesellschaft Kohle Mbh	Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
WO1999003848A1 (de)	1997-07-16	1999-01-28	Schering Aktiengesellschaft	Thiazolderivate, verfahren zur herstellung und verwendung
ATE368036T1 (de)	1997-08-09	2007-08-15	Bayer Schering Pharma Ag	Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6498257B1 (en) *	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
WO2000039276A2 (en) *	1998-12-23	2000-07-06	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone

2000
- 2000-02-17 PT PT00910219T patent/PT1157023E/pt unknown
- 2000-02-17 EE EEP200100437A patent/EE04852B1/xx unknown
- 2000-02-17 WO PCT/US2000/004068 patent/WO2000050423A1/en active IP Right Grant
- 2000-02-17 GE GEAP20006055A patent/GEP20033067B/en unknown
- 2000-02-17 NZ NZ513629A patent/NZ513629A/xx unknown
- 2000-02-17 CA CA2360452A patent/CA2360452C/en not_active Expired - Fee Related
- 2000-02-17 CN CNB008039461A patent/CN1205208C/zh not_active Expired - Fee Related
- 2000-02-17 JP JP2000601003A patent/JP4598957B2/ja not_active Expired - Fee Related
- 2000-02-17 ID IDW00200101797A patent/ID29829A/id unknown
- 2000-02-17 US US09/506,481 patent/US6262094B1/en not_active Expired - Lifetime
- 2000-02-17 EP EP00910219A patent/EP1157023B1/en not_active Expired - Lifetime
- 2000-02-17 MX MXPA01008374A patent/MXPA01008374A/es active IP Right Grant
- 2000-02-17 KR KR1020017010421A patent/KR100685336B1/ko not_active IP Right Cessation
- 2000-02-17 TW TW089102732A patent/TWI270546B/zh not_active IP Right Cessation
- 2000-02-17 TR TR2001/02401T patent/TR200102401T2/xx unknown
- 2000-02-17 ES ES00910219T patent/ES2209831T3/es not_active Expired - Lifetime
- 2000-02-17 BR BR0008379-8A patent/BR0008379A/pt not_active IP Right Cessation
- 2000-02-17 IL IL14450100A patent/IL144501A0/xx not_active IP Right Cessation
- 2000-02-17 DK DK00910219T patent/DK1157023T3/da active
- 2000-02-17 CZ CZ20012991A patent/CZ301498B6/cs not_active IP Right Cessation
- 2000-02-17 PL PL350179A patent/PL212545B1/pl unknown
- 2000-02-17 AU AU32348/00A patent/AU771089B2/en not_active Ceased
- 2000-02-17 DE DE60006649T patent/DE60006649T2/de not_active Expired - Lifetime
- 2000-02-17 RU RU2001125435/04A patent/RU2253652C2/ru not_active IP Right Cessation
- 2000-02-17 SK SK1078-2001A patent/SK287200B6/sk not_active IP Right Cessation
- 2000-02-17 AT AT00910219T patent/ATE254615T1/de active
- 2000-02-17 HU HU0200076A patent/HUP0200076A3/hu unknown
- 2000-02-21 MY MYPI20000629A patent/MY120601A/en unknown
- 2000-02-22 UY UY26024A patent/UY26024A1/es not_active Application Discontinuation
- 2000-02-22 AR ARP000100744A patent/AR028815A1/es unknown
- 2000-02-22 PE PE2000000140A patent/PE20001546A1/es not_active Application Discontinuation
- 2000-02-22 CO CO00012008A patent/CO5140093A1/es unknown
2001
- 2001-08-17 BG BG105830A patent/BG64987B1/bg unknown
- 2001-08-17 NO NO20014017A patent/NO320806B1/no not_active IP Right Cessation
- 2001-08-23 LV LV010126A patent/LV12755B/xx unknown
- 2001-08-24 LT LT2001086A patent/LT4944B/lt not_active IP Right Cessation
2002
- 2002-01-22 HK HK02100498.5A patent/HK1038923B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL144501A0 (en)	2002-05-23
CZ301498B6 (cs)	2010-03-24
NZ513629A (en)	2004-01-30
HK1038923A1 (en)	2002-04-04
HUP0200076A2 (hu)	2002-12-28
CO5140093A1 (es)	2002-03-22
EE04852B1 (et)	2007-06-15
HK1038923B (zh)	2004-03-19
MY120601A (en)	2005-11-30
HUP0200076A3 (en)	2003-01-28
DE60006649D1 (de)	2003-12-24
BG64987B1 (bg)	2006-11-30
SK10782001A3 (sk)	2002-03-05
EP1157023B1 (en)	2003-11-19
NO20014017L (no)	2001-10-17
KR20010102199A (ko)	2001-11-15
GEP20033067B (en)	2003-09-25
RU2253652C2 (ru)	2005-06-10
ATE254615T1 (de)	2003-12-15
CN1205208C (zh)	2005-06-08
LV12755B (lv)	2002-04-20
CZ20012991A3 (cs)	2002-01-16
PL350179A1 (en)	2002-11-18
TR200102401T2 (tr)	2001-12-21
WO2000050423A1 (en)	2000-08-31
US6262094B1 (en)	2001-07-17
PL212545B1 (pl)	2012-10-31
LT2001086A (en)	2002-04-25
EE200100437A (et)	2002-12-16
CA2360452C (en)	2011-07-26
BR0008379A (pt)	2002-09-24
AR028815A1 (es)	2003-05-28
PE20001546A1 (es)	2001-03-18
JP2002537395A (ja)	2002-11-05
NO320806B1 (no)	2006-01-30
KR100685336B1 (ko)	2007-02-23
DK1157023T3 (da)	2004-03-29
LV12755A (en)	2001-11-20
AU771089B2 (en)	2004-03-11
CN1341114A (zh)	2002-03-20
AU3234800A (en)	2000-09-14
MXPA01008374A (es)	2003-06-06
TWI270546B (en)	2007-01-11
LT4944B (lt)	2002-08-26
JP4598957B2 (ja)	2010-12-15
BG105830A (en)	2002-03-29
SK287200B6 (sk)	2010-03-08
ES2209831T3 (es)	2004-07-01
DE60006649T2 (de)	2004-09-30
EP1157023A1 (en)	2001-11-28
NO20014017D0 (no)	2001-08-17
ID29829A (id)	2001-10-11
CA2360452A1 (en)	2000-08-31
UY26024A1 (es)	2000-09-29

Publication	Publication Date	Title
PT1157023E (pt)	2004-03-31	Epotilonas modificadas em c-21
DK1079786T3 (da)	2002-12-23	Absorberende struktur i en absorberende artikel
ID25435A (id)	2000-10-05	Pakaian dalam sekali pakai
DE69909284D1 (de)	2003-08-07	Verbesserungen bei koaleszierfilter
DE60044873D1 (de)	2010-10-07	Orientierte biopolymermembrane
AR028622A1 (es)	2003-05-14	Derivados de tropano utiles en terapia
DE69923766D1 (de)	2005-03-24	Protonendonatoren in saugkörpern
PT1060695E (pt)	2005-01-31	Cadeira empilhavel
DE60043584D1 (de)	2010-02-04	Neigungsverstellvorrichtung
ID26890A (id)	2001-02-15	2-fenil-1-(4-(2-aminoetoksi) -benzil)-indol dalam kombinasinya dengan estrogen
DE60014662D1 (de)	2004-11-11	Verbesserungen in der schadstoffausstossregelung
DE60014883D1 (de)	2004-11-18	Genetisch veränderte stärken in panaden
DE60044218D1 (de)	2010-05-27	em
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
ATA7602000A (de)	2005-03-15	Verbundplatte
IT248325Y1 (it)	2003-01-28	Trinciatrice
DK1065098T3 (da)	2006-12-27	Arrangement i lastrum
FI4480U1 (fi)	2000-06-21	Hienonnuslaite
DE60005282D1 (de)	2003-10-23	Golfschlägerkopf, golfschläger und golfschlägerset
FI19992468A (fi)	2001-05-18	Tuoli
IT1307020B1 (it)	2001-10-23	Procedimento di n-denitrazione di n-nitro-dinitro-anilene in faseomogenea.
ATA90082000A (de)	2003-04-15	Sitzmöbel
BR7902842Y1 (pt)	2009-01-13	disposiÇço introduzida em quadro de distribuiÇço.
ITPA990010A3 (it)	2001-02-26	Sandwich in lattina
ITPA990009U1 (it)	2001-02-26	Sandwich in lattina